^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RET C634F

    i
    Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
    Entrez ID:
    5979
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    MOLECULAR AND PATHOLOGICAL PATTERNS OF TREATMENT FAILURE IN PATIENTS TREATED BY RET SELECTIVE INHIBITORS FOR METASTATIC MEDULLARY THYROID CARCINOMA (ATA 2022)
    Pts received RETi after a median number of 1 treatment line (range 0‐6) and 83% had received vandetanib (V) prior to RETi... By‐pass resistance MA may be the most frequent mechanism of progression under RETi. More aggressive histology may arise following proghression; further explorations are warranted.
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • RET (Ret Proto-Oncogene) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS G12D • RET mutation • RET M918T • KRAS G12 • NRAS G12 • KRAS A59T • RET V804L • RET C634* • RET C634F • RET V804*
    |
    Caprelsa (vandetanib)
    over2years
    RET Proto-Oncogene Mutational Analysis in 45 Iranian Patients Affected with Medullary Thyroid Carcinoma: Report of a New Variant. (PubMed, J Thyroid Res)
    RET mutation detection is a promising/golden screening test and provides an accurate presymptomatic diagnostic test for at-risk carriers (the siblings and offspring of the patients) to consider prophylactic thyroidectomy. Thus, according to the ATA recommendations, the screening of the RET proto-oncogene is indicated for patients with MTC.
    Clinical • Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation • RET M918T • RET C634R • RET C634Y • RET C618R • RET C634* • RET C634F • RET positive
    almost4years
    Case report for an adolescent with germline RET mutation and alveolar rhabdomyosarcoma. (PubMed, Cold Spring Harb Mol Case Stud)
    We also evaluated the use of JAK/STAT pathway inhibitors in the context of rhabdomyosarcomas bearing the FGFR4 G388R coding variant. Although the patient succumbed to his disease, study of the patient's tumor has generated insights into the biology of RET and other targets in rhabdomyosarcoma.
    Clinical • Journal
    |
    RET (Ret Proto-Oncogene) • FGFR4 (Fibroblast growth factor receptor 4) • CDK4 (Cyclin-dependent kinase 4) • FOXO1 (Forkhead box O1)
    |
    RET mutation • CDK4 amplification • FGFR4 amplification • RET C634F
    |
    Cabometyx (cabozantinib tablet)